Skip to main content

Table 6 Multivariable analyses of PFS and OS (Model 2)

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables PFS OS
HR 95% CI p value HR 95% CI p value
Age (years)    0.379    0.975
  ≤ 65 Ref.    Ref.   
 >65 1.204 0.796–1.824   0.993 0.640–1.540  
ECOG PS    0.487    0.483
 0 Ref.    Ref.   
 1 1.147 0.780–1.686   1.154 0.773–1.724  
Clinical stage    0.004**    0.004**
 IIIB Ref.    Ref.   
 IV 1.752 1.190–2.578   1.802 1.207–2.690  
First-line response    0.035*    0.015*
 CR/PR Ref.    Ref.   
 SD/PD 1.576 1.033–2.406   1.754 1.117–2.753  
Albumin    0.097    
 Decreased 1.367 0.945–1.978     
 Normal Ref.      
LMR_SUV    < 0.001***    < 0.001***
 Score 0 Ref.    Ref.   
 Score 1 2.017 1.233–3.300 0.005** 2.177 1.273–3.722 0.004**
 Score 2 3.421 1.903–6.148 < 0.001*** 4.573 2.441–8.569 < 0.001***
  1. PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, LMR lymphocyte-monocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001